Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Baricitinib Plus Danazol Versus Danazol for Patients With Steroid-resistant/Relapse Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Phase 2 Trial

NCT05852847 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05852847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05852847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Baricitinib Plus Danazol Versus Danazol for Patients With Steroid-resistant/Relapse Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Phase 2 Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 16, 2023
Completion date
May 31, 2025
Enrollment
216 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia